BioSpace News Archive

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock.

Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it plans to make a public offering of 3,000,000 shares of its common stock,

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, Chief Executive Officer, will participate in a fireside chat during the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference,

Moleculin Biotech, Inc.,today announced that the underwriters of its public offering announced February 3, 2021 have exercised in full their option to purchase an additional 2,141,052 shares of common stock

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:

Aethlon Medical, Inc., a medical device therapeutic company focused on developing products to diagnose and treat life and organ threatening diseases, reported financial results for its third quarter ended December 31, 2020 and provided an update on recent developments.

Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for tisotumab vedotin.

— Chris Lowe Promoted to Chief Operating Officer and Chief Financial Officer — Ted Monohon Promoted to Chief Accounting Officer —Drew Sukovich, Ph.D., RAC, Joins as Vice President, Regulatory and Quality

- Total Revenues of $270.1 Million for the Fourth Quarter of 2020, $987.5 Million for the Full Year 2020 - - GAAP Diluted EPS of $0.09 for the Fourth Quarter of 2020, $0.35 for the Full Year 2020 - - Non-GAAP Diluted EPS of $0.14 for the Fourth Quarter of 2020, $0.61 for the Full Year 2020 - - Conference Call and Webcast Today at 5:00 PM Eastern Time -

Core One Labs Inc. a biotechnology research and development life sciences enterprise focused on advancing psychedelic medicines to market, is pleased to announce preparations for filing a patent application encompassing its proprietary biosynthetic psilocybin production system.